Walgreens’ downfall as a publicly traded company ends with $10B take-private deal: We think Walgreens’ retail pharmacy will eventually get back on track. The company's aggressive push into healthcare delivery was its undoing.
Most US adults don’t want cuts to Medicaid funding: Broad support for the program among Republicans and Democrats runs counter to Republican lawmakers' proposed steep budget cuts that experts say can’t avoid Medicaid.
Pfizer rolls out genAI search tool for patients’ common health questions: The drugmaker wants to be a trusted destination for consumers at all stages of their health journeys. We explore if Pfizer can pull it off.
Novo Nordisk launches D2C platform, drops price of Wegovy for cash-pay patients: The move could start a marketing showdown—and possible price war—between Novo and Lilly.
Patients value digital health tools, but adoption lags at many medical practices: It’s now tablestakes for healthcare orgs to have a digital front door that allows consumers to use online tools to access care.
AbbVie shakes up obesity market: AbbVie’s entrance to the weight loss drug market could create more competition between Big Pharma with a vote of confidence in a GLP-1 alternative.
It launches with 200+ partners, aiming to reshape enterprise workflows—but adoption hurdles like trust issues and integration complexity could slow its impact.
Eli Lilly’s Oscars commercial slams unapproved drugs like compounded GLP-1s: The ad could help pharma companies rebuild trust with consumers.
Medical misinformation ‘infodemic’ on social media: Influencers are promoting misleading information about medical tests. Here’s what healthcare and pharma brands should be doing to combat it.
Microsoft, Google enhance genAI offerings for clinicians: We examine the race between startups, health tech companies, and Big Tech giants to show healthcare organizations how their AI tools will drive efficiency-–and why Microsoft could have a leg up on the competition.
What Gen Z wants from pharma: We present the data on how Gen Z feels about pharma communications and explore how marketers can more effectively reach younger consumers.
Healthcare stakeholders push Congress to make Medicare coverage of telehealth permanent: It’s set to expire at the end of March. We explore what’s at stake for seniors, many of whom are used to getting care remotely.
Placing Aria Gen 2 in research labs could help Meta gather real-world data—turning researchers into de facto product testers for its next wave of consumer smart glasses.
Doctors should ask their patients to write online reviews—and then respond to feedback: It will go a long way in attracting and retaining patients.
Trump issues executive order to make healthcare prices more transparent: Price rules finalized during his first term haven’t had an impact. Could it be different this time around?
Talks of a Walgreens take-private sale are ramping up again: Walgreens could be divided into three parts if the sale proceeds. We explore the likelihood of a deal going through and what it means for Walgreens’ future.
Only 18% of consumers have ever asked their doctor about a drug ad: But when they do, many patients walk away with a prescription for that medication. We explore how pharma marketers can get the most out of their ad campaigns.
Hims & Hers will still sell compounded semaglutide to some patients: The company isn’t ready to admit defeat in the battle between compounded GLP-1 sellers and Big Pharma. But Hims’ competitive advantage in the weight loss drug market is getting weaker.
US docs spend up to 3 hours per week correcting AI: Physicians’ liability concerns with AI can be addressed by having them involved with technology purchasing decisions.
DOJ will examine UnitedHealth’s Medicare billing practices: The Trump administration has made “waste, fraud, and abuse” a rallying cry. Now, we find out how serious they are about it.